Immunohistochemical expression of E-cadherin and N-cadherin in endometrioid endometrial carcinoma and its precursor lesions

Yadav, Sunita; Makkar, Annu; Agarwal, Preeti; Singh, U. S.; Goel, Madhu Mati

doi:10.1016/j.cegh.2023.101296

Cited by 1 publication

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, high expression of N-cadherin promotes aggressive behavior of the cancer cells, and low expression of protective E-cadherin (44% of cases) confirms the ongoing EMT process in the analyzed samples. Yadav et al [ 28 ] also found that the downregulation of E-cadherin (69% of cases) was associated with the upregulation of N-cadherin (82% of cases) in patients with EC. This is also in line with other studies showing a significant reduction in E-cadherin levels in EC compared with the proliferative endometrium [ 29 ].…”

Section: Discussionmentioning

confidence: 98%

“…Additionally, cells undergoing EMT acquire mesenchymal markers such as vimentin, fibronectin, and SPARC, among others, facilitating their interaction with the stroma, thereby promoting invasion and metastasis. Throughout tumor progression, E-cadherin can be functionally impaired via various mechanisms, including somatic mutation, downregulation of gene expression through promoter methylation, and/or transcriptional repression [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of E-Cadherin and N-Cadherin in the Endocervix as a Predictive Factor in Patients with Endometrial Cancer

Frąszczak,

Barczyński,

Tylus

et al. 2024

IJMS

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most common gynecological malignancy. This study aimed to evaluate the expression of E-cadherin and N-cadherin in primary endometrial lesions and the endocervix in patients with EC to identify noninvasive predictive factors. In this single-center retrospective study, data on 101 patients who underwent surgery for EC were collected. The immunohistochemical expression of E-cadherin and N-cadherin was assessed depending on the tumor grade, location, and cell differentiation. Correlations between E-cadherin and N-cadherin levels in the endocervix and the primary tumor were determined. The degree of histological tumor differentiation significantly affected E-cadherin expression (p = 0.04) but had no impact on N-cadherin levels. In type II EC, the expression of both cadherins in the tumor tissue differed from their endocervical levels. The expression of E-cadherin differed significantly between the endocervix (p < 0.001) and the tumor (p = 0.001), depending on the type of EC. The expression of E-cadherin was related to the N-cadherin level only in the endocervix in patients with type II EC (p = 0.02). E-cadherin and N-cadherin were expressed in the endocervix in patients with EC. The expression of cadherins, determined during cervical cytology, may be a valuable clinical marker of EC.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%